Pyrotinib
- Generic Name
- Pyrotinib
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy
- Conditions
- HER2 Exon 20 MutationNon-squamous NSCLC
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 151
- Registration Number
- NCT04447118
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
🇧🇪Antwerp University Hospital (UZA), Edegem, Belgium
PLATFORM Study of Precision Medicine for Rare Tumors
- Conditions
- Rare Tumor
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-11
- Target Recruit Count
- 770
- Registration Number
- NCT04423185
- Locations
- 🇨🇳
Cancer hospital Chinese Academy of Medical Sciences, Beijing, China
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 86
- Registration Number
- NCT04407988
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
- Conditions
- Breast Cancer Invasive
- Interventions
- Drug: Physician's choiceDrug: EC chemotherapyProcedure: Surgery
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 216
- Registration Number
- NCT04398914
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.
- Conditions
- TNBC - Triple-Negative Breast Cancer
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 139
- Registration Number
- NCT04395989
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT04382300
- Locations
- 🇨🇳
Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Target Recruit Count
- 40
- Registration Number
- NCT04380012
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medical, Hangzhou, Zhejiang, China
Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 97
- Registration Number
- NCT04367090
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer
- Conditions
- Breast CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-04-21
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 319
- Registration Number
- NCT04355858
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
Effect of Low-fat Diet on the Pharmacokinetics of Pyrotinib in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT04315493
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.